Metabolic effects of pivalate in isolated rat hepatocytes

doi:10.1016/S0041-008X(05)80012-2

Toxicology and Applied Pharmacology

Volume 110, Issue 2, 1 September 1991, Pages 295-302

https://doi.org/10.1016/S0041-008X(05)80012-2 Get rights and content

Abstract

Pivalate (trimethylacetic acid) administration in humans or rat has been reported to cause metabolic changes and increased urinary carnitine excretion secondary to pivaloylcarnitine generation. As pivaloylcarnitine formation is dependent on intra-cellular activation of pivalate, the effects of pivalate on cellular coenzyme A and acyl-CoA contents and oxidative metabolism were defined using isolated rat hepatocytes. During incubations with pivalate (1.0 mm), hepatocyte coenzyme A content fell to <0.05 nmol/10⁶ cells (vs 0.97 nmol/10⁶ cells in the absence of pivalate) as pivaloyl-CoA accumulated. Pivalate (5 mm) inhibited ¹⁴CO₂ generation from 10 mm [1-¹⁴C]pyruvate by 34%, but had no effect on 0.8 mm [1-¹⁴C]palmitate oxidation. Pivaloyl-CoA was a substrate for hepatocyte carnitine acyltransferase activity, but supported acylcarnitine formation at rates only 10–20% of those observed with equimolar acetyl-CoA or isovaleryl-CoA as substrates. Thus, hepatocytes activate pivalate to pivaloyl-CoA, which can then be used as a substrate for pivaloylcarnitine formation. The sequestration of hepatocyte coenzyme A as pivaloyl-CoA is associated with inhibition of pyruvate oxidation. As with other organic carboxylic acids, activation of pivalate to the coenzyme A thioester is an important aspect in the biochemical toxicology of the compound.

References (38)

Al-ArifA. et al.
Synthesis of fatty acyl-CoA and other thiol esters using N-hydroxysuccinimide esters of fatty acids
J. Lipid Res.
(1969)
BrassE.P. et al.
Inhibition of glucagon-stimulated hepatic glycogenolysis by E-series prostaglandins
FEBS Lett.
(1984)
BrassE.P. et al.
Interactions of propionate and carnitine metabolism in isolated rat hepatocytes
Metabolism
(1987)
ColucciW.J. et al.
Carnitine acetyltransferase: A review of its biology, enzymology, and bioorganic chemistry
Bioorg. Chem.
(1988)
CorkeyB.E. et al.
Assay of short-chain acyl coenzyme A intermediates in tissue extracts by high-performance liquid chromatography
Anal. Biochem.
(1981)
FritzI.B. et al.
Carnitine acetyltransferase. II. Inhibition by carnitine analogues and by sulfhydryl reagents
J. Biol. Chem.
(1965)
FukamiM.H. et al.
On the mechanism of inhibition of fatty acid oxidation by 4-pentenoic acid in rat liver mitochondria
J. Biol. Chem.
(1971)
GornallA.G. et al.
Determination of serum proteins by means of the biuret reaction
J. Biol. Chem.
(1949)
GregersenN.
The specific inhibition of the pyruvate dehydrogenase complex from pig kidney by propionyl-CoA and isovaleryl-CoA
Biochem. Med.
(1981)
HuckleW.R. et al.
Purification and properties of carnitine acetyltransferases from bovine spermatozoa and heart
Arch. Biochem. Biophys.
(1983)

MarkwellM.A. et al.

Differential increase of hepatic peroxisomal, mitochondrial and microsomal carnitine acyltransferases in clofibrate-fed rats

Biochem. Pharmacol.

(1977)

McCuneS.A. et al.

Inhibition of hepatic gluconeogenesis and lipogenesis by benzoic acid, p-tert.-butylbenzoic acid, and a structurally related hypolipidemic agent SC-33459

Arch. Biochem. Biophys.

(1982)

MeleghB. et al.

Pivampicillin-promoted excretion of pivaloylcarnitine in humans

Biochem. Pharmacol.

(1987)

MeleghB. et al.

Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate

Biochem. Med. Met. Biol.

(1990)

SinkulaA.A. et al.

Rationale for design of biologically reversible drug derivatives: Prodrugs

J. Pharm. Sci.

(1975)

SolbergH.E. et al.

Formation of branched chain acylcarnitines in mitochondria

Biochim. Biophys. Acta

(1970)

Walajtys-RodeE. et al.

Effects of branched-chain alpha-ketoacids on the metabolism of isolated rat liver cells

J. Biol. Chem.

(1980)

AllredJ.B. et al.

Determination of coenzyme A and acetyl-coenzyme A in tissue extracts

Anal. Biochem.

(1969)

BerryM.N. et al.

High-yield preparation of isolated rat liver parenchymal cells

J. Biol. Chem.

(1969)

Cited by (31)

A novel small molecule approach for the treatment of propionic and methylmalonic acidemias
2021, Molecular Genetics and Metabolism
Citation Excerpt :
After hydrolysis of the prodrug, pivalate can be further biotransformed by acyl-CoA synthases to form pivaloyl-CoA [31]. The production of pivaloyl-CoA in isolated hepatocytes induced only minimal inhibition of pyruvate dehydrogenase and had no effect on β-oxidation [32,33]. This is in stark contrast to the profound inhibition of both pyruvate dehydrogenase and β-oxidation induced by propionyl-CoA [17,20,34].
Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA) are inborn errors of metabolism affecting the catabolism of valine, isoleucine, methionine, threonine and odd-chain fatty acids. These are multi-organ disorders caused by the enzymatic deficiency of propionyl-CoA carboxylase (PCC) or methylmalonyl-CoA mutase (MUT), resulting in the accumulation of propionyl-coenzyme A (P-CoA) and methylmalonyl-CoA (M-CoA in MMA only). Primary metabolites of these CoA esters include 2-methylcitric acid (MCA), propionyl-carnitine (C3), and 3-hydroxypropionic acid, which are detectable in both PA and MMA, and methylmalonic acid, which is detectable in MMA patients only (Chapman et al., 2012). We deployed liver cell-based models that utilized PA and MMA patient-derived primary hepatocytes to validate a small molecule therapy for PA and MMA patients. The small molecule, HST5040, resulted in a dose-dependent reduction in the levels of P-CoA, M-CoA (in MMA) and the disease-relevant biomarkers C3, MCA, and methylmalonic acid (in MMA). A putative working model of how HST5040 reduces the P-CoA and its derived metabolites involves the conversion of HST5040 to HST5040-CoA driving the redistribution of free and conjugated CoA pools, resulting in the differential reduction of the aberrantly high P-CoA and M-CoA. The reduction of P-CoA and M-CoA, either by slowing production (due to increased demands on the free CoA (CoASH) pool) or enhancing clearance (to replenish the CoASH pool), results in a net decrease in the CoA-derived metabolites (C3, MCA and MMA (MMA only)). A Phase 2 study in PA and MMA patients will be initiated in the United States.
Identification of an isoform catalyzing the CoA conjugation of nonsteroidal anti-inflammatory drugs and the evaluation of the expression levels of acyl-CoA synthetases in the human liver
2021, Biochemical Pharmacology
Citation Excerpt :
As the latter mechanism, the formation of CoA conjugates would be involved. As another mechanism, the excessive consumption of cellular CoA by CoA conjugation reaction, which may cause microvesicular steatosis of the liver [28,29], has been considered, because CoA is required for the formation of acetyl-CoA in glycolysis [30] and in β-oxidation of fatty acids [31]. In addition, a decrease in NADH, which is produced in the tricarboxylic acid cycle driven by acetyl-CoA, may cause a decrease in the production of ATP, which is essential for cellular function [32].
Nonsteroidal anti-inflammatory drugs (NSAIDs) containing carboxylic acid are conjugated with coenzyme A (CoA) or glucuronic acid in the body. It has been suggested that these conjugates are associated with toxicities, such as liver injury and anaphylaxis, through their binding via trans-acylation to cellular proteins. Although studies on glucuronidation have progressed, studies on CoA conjugation of drugs catalyzed by acyl-CoA synthetase (ACS) enzymes are still in the early stages. This study aimed to clarify the human ACS isoforms responsible for CoA-conjugation of NSAIDs through consideration of the hepatic expression levels of ACS isoforms. We found that among 10 types of NSAIDs, propionic acid-class NSAIDs, namely, alminoprofen, flurbiprofen, ibuprofen, ketoprofen, and loxoprofen, were conjugated with CoA in the human liver, whereas NSAIDs in the other classes, including diclofenac and mefenamic acid, were not. qRT-PCR revealed that among the 26 ACS isoforms, ACSL1 was the most highly expressed in the human liver, followed by ACSM2B. The propionic acid-class NSAIDs were conjugated with CoA by recombinant human ACSL1. The protein binding abilities of the CoA conjugates and the glucuronide forms of propionic acid-class NSAIDs were compared as an index of toxicity. The CoA conjugates had stronger adduct formation with liver microsomal proteins than glucuronides for all 5 propionic acid-class NSAIDs. In conclusion, we found that propionic acid-class NSAIDs could be conjugated to CoA by ACSL1 in the human liver to form CoA conjugates, which likely cause toxicity by protein adduct formation.
Pivalate lowers litter sizes and weights in female rats independent of its effect on carnitine status
2007, Reproductive Toxicology
The present study investigated whether treatment of female rats with pivalate affects their reproductive function. Therefore, two experiments with female rats were performed. The first experiment included two groups of rats which received drinking water without (control) or with 20 mmol pivalate/L. The second experiment included a control group (which received drinking water without pivalate and a diet without added carnitine) and four groups which received drinking water with 20 mmol/L pivalate and diets without or with 1, 3 or 5 g added carnitine/kg, respectively. In both experiments, rats treated with pivalate had a lower number of pups born alive and, as a consequence of this, lower litter weights than control rats (p < 0.05); pup weights were not altered by pivalate treatment. Supplementation of dietary carnitine in Experiment 2 increased plasma and tissue carnitine concentration even in excess of those in control rats but did not restore normal litter sizes. This study shows for the first time that pivalate affects the reproductive function in female rats independent of its effect on the carnitine status.
Possible mechanism for species difference on the toxicity of pivalic acid between dogs and rats
2006, Toxicology and Applied Pharmacology
In a high dose toxicity study of pivalic acid (PA), PA caused skeletal muscle disorder in dog, and a significant increase of pivaloyl carnitine (PC) was observed in canine muscle, but not in rat muscle. In order to understand species difference of the toxicity of PA, we compared the in vitro metabolism of PA among dog, rat and rabbit, especially focussing on the carnitine conjugate. Canine muscle showed low, but significant carnitine conjugating activity, while that of rat was negligible. Canine kidney mitochondria had significant activity in the pivaloyl CoA synthesis (7 nmol/mg protein/h), but muscle mitochondria showed only trace activity. Both kidney and muscle mitochondria displayed similar carnitine acyltransferase activity (2–3 nmol/mg protein/h) towards pivaloyl CoA. On the other hand, with respect to the activity of carnitine acyltransferase in the reverse direction using PC as substrate, canine muscle mitochondria showed higher activity than that of kidney mitochondria. This means that PC is not the final stable metabolite, but is converted easily to pivaloyl CoA in canine muscle. These results suggest one of the possible mechanisms for canine selective muscle disorder to be as follows. Only canine muscle can metabolize PA to its carnitine conjugate slowly, but significantly. In canine muscle, PC is not the final stable metabolite; it is easily converted to pivaloyl CoA. As carnitine conjugation is thought to be the only detoxification metabolic route in canine muscle, under certain circumstances such as carnitine deficiency, the risk of exposure with toxic pivaloyl CoA might increase and the CoASH pool in canine muscle might be exhausted, resulting in toxicity in canine muscle.
Identification of the amino acids of human serum albumin involved in the reaction with the naproxen acyl coenzyme A thioester using liquid chromatography combined with fluorescence and mass spectrometric detection
2003, Analytical Biochemistry
Xenobiotic carboxylic acids, that via their metabolites covalently modify proteins, have been associated with serious side effects in man. Such reactive metabolites may be acyl glucuronides or alternatively, the corresponding acyl-CoA thioesters. In this study, the reaction of a model xenobiotic acyl-CoA, the naproxen-CoA, with human serum albumin (HSA), was characterized by high-performance liquid chromatography employing fluorescence and mass spectrometric detection. One mM naproxen-CoA was incubated for 6 h with HSA (0.45 mM) at 37 °C in a 0.1 M phosphate buffer (pH 7.4). The tryptic digest of the reduced and alkylated protein was analyzed in order to identify the amino acids in the sequence that were covalently modified with naproxen. Fluorescent peptides, that represented naproxen-modified peptides, were characterized using HPLC–MS–MS and HPLC–MS in zoom scan mode, which provided information on the structure and the charge of the modified peptides. The naproxen-CoA reacted predominantly with lysine 199, lysine 541, and lysine 351, which was in agreement with the binding pattern that has previously been reported for the reactive acyl glucuronides and their reaction with HSA.
Chemical reactivity of the naproxen acyl glucuronide and the naproxen coenzyme A thioester towards bionucleophiles
2002, Journal of Pharmaceutical and Biomedical Analysis
Drugs may be metabolised to reactive electrophilic species that spontaneously react with proteins. The presence of such drug–protein adducts has been associated with drug toxicity. In this study, the reactivity of the major metabolite of naproxen—the 1-β-O-glucuronide (Nap-GlcU)—was compared to the corresponding naproxen coenzyme A (Nap-CoA) thioester. The reactivity of the two metabolites was assessed in vitro in a phosphate buffer (pH 7.4; 0.1 M) at 37 °C towards the model bionucleophiles glutathione and human serum albumin (HSA). The reaction between the electrophilic species (Nap-GlcU and Nap-CoA) and glutathione forming the Nap-glutathione conjugate was monitored using LC–MS–MS and LC–UV, respectively. It was shown that Nap-CoA resulted in an approximate 100-fold higher formation of Nap-glutathione conjugate than Nap-GlcU. The presence of Nap-CoA also resulted in acylated HSA with a rate and a yield that was significantly higher than reported for Nap-GlcU. In summary, the data suggest that CoA metabolites may be more reactive species than acyl glucuronides that previously have been associated with severe drug related side effects in vivo.

View all citing articles on Scopus

View full text

Metabolic effects of pivalate in isolated rat hepatocytes

Abstract

J. Lipid Res.

FEBS Lett.

Metabolism

Bioorg. Chem.

Anal. Biochem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Biochem. Med.

Arch. Biochem. Biophys.

Biochem. Pharmacol.

Arch. Biochem. Biophys.

Biochem. Pharmacol.

Biochem. Med. Met. Biol.

J. Pharm. Sci.

Biochim. Biophys. Acta

J. Biol. Chem.

Determination of coenzyme A and acetyl-coenzyme A in tissue extracts

Anal. Biochem.

High-yield preparation of isolated rat liver parenchymal cells

J. Biol. Chem.